Wellington Management Group LLP Takes $25.63 Million Position in Upstream Bio, Inc. (NASDAQ:UPB)

Wellington Management Group LLP acquired a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,583,154 shares of the company's stock, valued at approximately $25,632,000. Wellington Management Group LLP owned about 2.95% of Upstream Bio at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in UPB. Norges Bank purchased a new stake in shares of Upstream Bio in the fourth quarter worth $16,440,000. Charles Schwab Investment Management Inc. bought a new position in shares of Upstream Bio in the 4th quarter valued at about $2,225,000. Moody Aldrich Partners LLC bought a new stake in shares of Upstream Bio in the 4th quarter valued at approximately $1,229,000. JPMorgan Chase & Co. bought a new position in Upstream Bio during the fourth quarter valued at $786,000. Finally, Bank of New York Mellon Corp bought a new position in Upstream Bio during the 4th quarter valued at about $607,000.

Upstream Bio Price Performance

NASDAQ:UPB traded up $0.97 during mid-day trading on Friday, reaching $7.37. The company's stock had a trading volume of 303,708 shares, compared to its average volume of 327,123. The business's fifty day simple moving average is $7.68. Upstream Bio, Inc. has a 1 year low of $5.14 and a 1 year high of $29.46.

Upstream Bio Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.